top of page
Search

HNCIG-6/NRG HN002 RESULTS PUBLISHED IN JCO

  • Writer: Michelle Gill
    Michelle Gill
  • Mar 10, 2023
  • 1 min read


January 28, 2021

This randomized phase II trial for good-risk HPV-associated OPSCC compared reduced-dose radiation (60 Gy) with or without concurrent weekly cisplatin. The RT-only arm was accelerated at 6 fractions per week. The accelerated reduced-dose radiation alone arm failed to meet statistical conditions for PFS acceptability, whereas the CRT arm did, justifying its advancement as a study arm of NRG-HN005. https://ascopubs.org/doi/full/10.1200/JCO.20.03128

Head & Neck Cancer International Group

©2023 by Head & Neck Cancer International Group.

bottom of page